Stockreport

Structure Therapeutics Phase 2 Obesity Data Shifts Focus To Phase 3 [Yahoo! Finance]

Structure Therapeutics Inc.  (GPCR) 
PDF Structure Therapeutics (NasdaqGM:GPCR) reported positive topline Phase 2 results for its oral GLP-1 receptor agonist aleniglipron in obesity. The data indicate strong [Read more]